SCHEMBL25814802

SCHEMBL25814802

Cc1c(Br)cc(C(=O)c2c(C(C)O)oc3ccccc23)cc1Br

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EYA3 Q99504 8/20 0.81
▸ CYP2C19 P33261 10/20 0.57
▸ CYP2C9 P11712 4/20 0.51
▸ TTR P02766 3/20 0.51
▸ NR1H4 Q96RI1 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ ABCB11 O95342 2/20 0.51
▸ LMNA P02545 2/20 0.51
▸ PGR P06401 2/20 0.51
▸ ADRA2A P08913 2/20 0.51
▸ TBXA2R P21731 2/20 0.51
▸ OPRM1 P35372 2/20 0.51
▸ SLC6A3 Q01959 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ EYA2 O00167 1/20 0.51
▸ ABCC4 O15439 1/20 0.51
▸ PLIN1 O60240 1/20 0.51
▸ NR1I2 O75469 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Poztinurad SCHEMBL29569243 0.90 EYA3 (1.00) EYA3CYP2C19CYP2C9TTRNR1H4
Poztinurad SCHEMBL15698085 0.90 EYA3 (1.00) EYA3CYP2C19CYP2C9TTRNR1H4
SCHEMBL25814848 0.86 EYA3 (0.62) EYA3CYP2C19CYP2C9TTRNR1H4
SCHEMBL15698033 0.81 EYA3 (0.83) EYA3CYP2C19CYP2C9TTRNR1H4
SCHEMBL25892406 0.80 EYA3 (0.81) EYA3CYP2C19CYP2C9TTRNR1H4
SCHEMBL20702031 0.79 EYA3 (0.80) EYA3CYP2C19CYP2C9TTRNR1H4
SCHEMBL18058593 0.78 CYP2C19 (0.81) EYA3CYP2C19CYP2C9TTRNR1H4
SCHEMBL25815018 0.77 EYA3 (0.77) EYA3CYP2C19CYP2C9TTRNR1H4
SCHEMBL22680472 0.77 EYA3 (0.77) EYA3CYP2C19CYP2C9TTRNR1H4
SCHEMBL25814830 0.76 TTR (0.64) EYA3CYP2C19CYP2C9TTRNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ARTHROSI THERAPEUTICS, INC. 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ATP6V1B1, REN, CYP27B1 EYA3 3141/4885CYP2C19 826/4885CYP2C9 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback